| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Director
2 companies
Edmund Harrigan is Director at ACAD, with reported holdings spanning 2 companies. Edmund Harrigan's net worth is not public. Form 4 filings only show shares in the companies where this person is an insider; those holdings are worth an estimated $3.6M at current prices.
Edmund Harrigan's largest disclosed position is in INCY as Director, worth about $2.7M.
Edmund Harrigan has 50 Form 4 filings on record from November 2015 to September 2026, across 2 companies: Director at Incyte (INCY), 2019–2026; Director at ACADIA Pharmaceuticals (ACAD), 2015–2026.
The 72 reported transactions were 36 stock awards, 29 option or other derivative awards, 6 option exercises and 1 open-market purchase.
Counted by filing, the open-market trades come to 1 purchase worth about $33K and no sales.
The only open-market purchase was 1,000 shares of ACAD at an average $32.97 on August 16, 2016, about $33K.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|
| Aug 16, 2016 | ACAD Acadia Pharmaceuticals Inc | Director | Buy | 1,000 | $32.97 | $32,970.00 | New |